Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 12, pp 3879–3887 | Cite as

Use of Panitumumab-IRDye800 to Image Microscopic Head and Neck Cancer in an Orthotopic Surgical Model

  • C. Hope Heath
  • Nicholas L. Deep
  • Larissa Sweeny
  • Kurt R. Zinn
  • Eben L. RosenthalEmail author
Head and Neck Oncology

Abstract

Background

Fluorescence imaging hardware (SPY) has recently been developed for intraoperative assessment of blood flow via detection of probes emitting in the near-infrared (NIR) spectrum. This study sought to determine if this imaging system was capable of detecting micrometastatic head and neck squamous cell carcinoma (HNSCC) in preclinical models.

Methods

A NIR fluorescent probe (IRDye800CW) was covalently linked to a monoclonal antibody targeting epidermal growth factor receptor (EGFR; panitumumab) or nonspecific IgG. HNSCC flank (SCC-1) and orthotopic (FADU and OSC19) xenografts were imaged 48–96 h after systemic injection of labeled panitumumab or IgG. The primary tumor and regional lymph nodes were dissected using fluorescence guidance with the SPY system and grossly assessed with a charge-coupled NIR system (Pearl). Histologic slides were also imaged with a NIR charged-coupled device (Odyssey) and fluorescence intensity was correlated with pathologic confirmation of disease.

Results

Orthotopic tongue tumors were clearly delineated from normal tissue with tumor-to-background ratios of 2.9 (Pearl) and 2.3 (SPY). Disease detection was significantly improved with panitumumab-IRDye compared to IgG-IRDye800 (P < 0.05). Tissue biopsy samples (average size 3.7 mm) positive for fluorescence were confirmed for pathologic disease by histology and immunohistochemistry (n = 25 of 25). Biopsy samples of nonfluorescent tissue were proven to be negative for malignancy (n = 28 of 28). The SPY was able to detect regional lymph node metastasis (<1.0 mm) and microscopic areas of disease. Standard histological assessment in both frozen and paraffin-embedded histologic specimens was augmented using the Odyssey.

Conclusions

Panitumumab-IRDye800 may have clinical utility in detection and removal of microscopic HNSCC using existing intraoperative optical imaging hardware and may augment analysis of frozen and permanent pathology.

Keywords

Epidermal Growth Factor Receptor Human Epidermal Growth Factor Receptor Cetuximab Indocyanine Green Neck Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

Supported in part by a grant from NIDCR (R21DE019232) and equipment donated by Novadaq. The authors thank Yolanda Hartman for running the Western blot assays.

Supplementary material

Supplementary material 1 (M4V 30,045 kb)

References

  1. 1.
    Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol. 2002;29:45–54.PubMedGoogle Scholar
  2. 2.
    Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, et al. (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 52:1778–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Themelis G, Yoo JS, Soh KS, et al. Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt. 2009;14:064012.CrossRefPubMedGoogle Scholar
  4. 4.
    Keereweer S, Kerrebijn JD, van Driel PB, et al. Optical image-guided surgery—where do we stand? Mol Imaging Biol. 2011;13:199–207.CrossRefPubMedGoogle Scholar
  5. 5.
    Keereweer S, Kerrebijn JD, Mol IM, et al. Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis. Head Neck. 2011. doi: 10.1002/hed.21861.
  6. 6.
    Biosciences L-C. 2007IRDye(R) 800CW protein labeling kit—high MW. Lincoln, NE: Li-Cor Biosciences; 2007. p. 1–9.Google Scholar
  7. 7.
    Reuthebuch O, Haussler A, Genoni M, et al. Novadaq SPY: intraoperative quality assessment in off-pump coronary artery bypass grafting. Chest. 2004;125:418–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Gleysteen JP, Newman JR, Chhieng D, et al. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck. 2008;30:782–9.CrossRefPubMedGoogle Scholar
  9. 9.
    van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med. 2011;17:1315–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Pleijhuis RG, Graafland M, de Vries J, et al. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol. 2009;16:2717–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Rosenthal EL, Kulbersh BD, Duncan RD, et al. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope. 2006;116:1636–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Gleysteen JP, Duncan RD, Magnuson JS, et al. Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther. 2007;6:1181–5.PubMedGoogle Scholar
  13. 13.
    Kulbersh BD, Duncan RD, Magnuson JS, et al. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg. 2007;133:511–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Marshall MV, Draney D, Sevick-Muraca EM, Olive DM. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol. 2010;12:583–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt. 2007;12:024017.CrossRefPubMedGoogle Scholar
  16. 16.
    Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol. 2004;31:734–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Withrow KP, Gleysteen JP, Safavy A, et al. Assessment of indocyanine green–labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg. 2007;137:729–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Remsen KA, Lucente FE, Biller HF. Reliability of frozen section diagnosis in head and neck neoplasms. Laryngoscope. 1984;94:519–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Gandour-Edwards RF, Donald PJ, Lie JT. Clinical utility of intraoperative frozen section diagnosis in head and neck surgery: a quality assurance perspective. Head Neck. 1993;15:373–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Keereweer S, Sterenborg HJ, Kerrebijn JD, et al. Image-guided surgery in head and neck cancer: current practice and future directions of optical imaging. Head Neck. 2012;34:120–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Zijlstra A, Mellor R, Panzarella G, et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 2002;62:7083–92.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • C. Hope Heath
    • 1
  • Nicholas L. Deep
    • 1
  • Larissa Sweeny
    • 1
  • Kurt R. Zinn
    • 2
  • Eben L. Rosenthal
    • 1
    Email author
  1. 1.Department of SurgeryUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of RadiologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations